Norway
· Delayed Price · Currency is NOK Lytix Biopharma AS Statistics
Total Valuation
Lytix Biopharma AS has a market cap or net worth of NOK 287.74 million. The enterprise value is 247.03 million.
| Market Cap | 287.74M |
| Enterprise Value | 247.03M |
Important Dates
The next estimated earnings date is Thursday, February 13, 2025.
| Earnings Date | Feb 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Lytix Biopharma AS has 49.61 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 49.61M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 11.97% |
| Float | 19.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 7.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.05 |
| EV / Sales | 22.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.07, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.07 |
| Quick Ratio | 3.07 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.79 |
Financial Efficiency
Return on equity (ROE) is -153.00% and return on invested capital (ROIC) is -95.37%.
| Return on Equity (ROE) | -153.00% |
| Return on Assets (ROA) | -75.91% |
| Return on Capital (ROIC) | -95.37% |
| Revenue Per Employee | 1.34M |
| Profits Per Employee | -10.12M |
| Employee Count | 8 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.01% in the last 52 weeks. The beta is -0.61, so Lytix Biopharma AS's price volatility has been lower than the market average.
| Beta (5Y) | -0.61 |
| 52-Week Price Change | -11.01% |
| 50-Day Moving Average | 6.46 |
| 200-Day Moving Average | 7.39 |
| Relative Strength Index (RSI) | 42.41 |
| Average Volume (20 Days) | 536,002 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lytix Biopharma AS had revenue of NOK 10.76 million and -80.92 million in losses.
| Revenue | 10.76M |
| Gross Profit | 10.76M |
| Operating Income | -82.86M |
| Pretax Income | -80.92M |
| Net Income | -80.92M |
| EBITDA | -82.79M |
| EBIT | -82.86M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 43.53 million in cash and 2.82 million in debt, giving a net cash position of 40.71 million or 0.82 per share.
| Cash & Cash Equivalents | 43.53M |
| Total Debt | 2.82M |
| Net Cash | 40.71M |
| Net Cash Per Share | 0.82 |
| Equity (Book Value) | 36.83M |
| Book Value Per Share | n/a |
| Working Capital | 36.05M |
Cash Flow
| Operating Cash Flow | -81.91M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -770.24% |
| Pretax Margin | -752.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lytix Biopharma AS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |